top of page
News
Search
NeoMatrix Therapeutics (NMT) Welcomes Joachim Kohn, PhD, FBSE as Chief Scientific Advisor
Neomatrix Therapeutics, Inc. is pleased to announce that Joachim Kohn, PhD has joined the company as its Chief Scientific Advisor. Â Dr....
Apr 22
James Mackay, PhD, joins Neomatrix Therapeutics, Inc. as Chief Business Advisor
Experienced Business Advisor who has led several therapeutics to market joins NeoMatrix Therapeutics, Inc. Â NeoMatrix Therapeutics, Inc....
Apr 18
NeoMatrix Therapeutics Peptide Discovery Advances Treatment of Burn Injury
Novel Peptide Progresses to Phase 2 for the Treatment of Severe Burns STONY BROOK, NY, February 5, 2025 (EINPresswire.com) – NeoMatrix...
Feb 13
NeoMatrix Announces Positive Topline Phase 1 Data for NMT-cNP8
NeoMatrix Therapeutics (NMT) Peptide Discovery Advances Treatment of Burn Injury. Novel Peptide Shows Promise for the Treatment of Severe...
Feb 13
NeoMatrix Announces Positive Topline Phase 1 Data for NMT-cP12
- Novel Peptide to Advance to Phase 2 for the Treatment of Severe Burns -
Sep 24, 2020
NeoMatrix Therapeutics Enters Clinical Stage as IND for NMT-cP12 Goes Into Effect
- Potential First-in-Class Treatment for Serious Burn Injuries Targets PDGF -
Oct 31, 2017
bottom of page